$3.180
-0.206 (-6.47%)Al cierre
- High
- 3.420
- Open
- 3.420
- VWAP
- 3.25
- Vol
- 48.46K
- Mkt Cap
- 12.78M
- Low
- 3.160
- Amount
- 157.66K
- EV/EBITDA, TTM
- -0.03
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
AI analysis of Can Fite Biopharma Ltd (CANF)
buyCan Fite Biopharma Ltd (CANF) is a good buy right now due to its current trading price of $3.40, which is significantly below the analyst price target of $8, suggesting a potential upside of 135%. Additionally, the stock has shown a positive trend with a 5-day change of +2.10% and a 20-day change of +7.94%. The main risk is its negative earnings per share (EPS) forecast of -10.86 for Q4 2024, indicating ongoing financial challenges.
Analyst Ratings (2)
H.C. Wainwright
$8
2026-07-02
H.C. Wainwright
2026-07-02
Precio objetivo
$8
D. Boral Capital
$7
2026-05-13
D. Boral Capital
2026-05-13
Precio objetivo
$7
H.C. Wainwright
$5
2026-05-12
H.C. Wainwright
2026-05-12
Precio objetivo
$5
D. Boral Capital
—
2025-12-24
D. Boral Capital
2025-12-24
Precio objetivo
—
D. Boral Capital
$10
2025-04-15
D. Boral Capital
2025-04-15
Precio objetivo
$10
Métricas de valoración
Cronología de eventos
Noticias
9.008-17NASDAQ.COMCan-Fite BioPharma Reports Positive Preclinical Results for Namodenoson
9.008-12NewsfilterCan-Fite BioPharma Secures FDA Fast Track and Orphan Drug Designations
- 9.008-03Newsfilter
Can-Fite Submits Phase 2 Clinical Study Protocol for Lowe Syndrome
- 9.007-06Newsfilter
Can-Fite BioPharma Completes Patient Enrollment for Psoriasis Clinical Trial
9.007-06Yahoo FinanceCan-Fite BioPharma Completes Enrollment of 247 Patients in Phase 3 Study
CANF FAQ — answered by Alphio AI
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Can Fite Biopharma Ltd (CANF) is a good buy right now due to its current trading price of $3.40, which is significantly below the analyst price target of $8, suggesting a potential upside of 135%. Additionally, the stock has shown a positive trend with a 5-day change of +2.10% and a 20-day change of +7.94%. The main risk is its negative earnings per share (EPS) forecast of -10.86 for Q4 2024, indicating ongoing financial challenges.
2 analysts cover CANF: 2 rate it Buy, 0 Hold and 0 Sell.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.